TCA
ROIV icon

Troluce Capital Advisors’s Roivant Sciences ROIV Stock Holding History

Troluce Capital Advisors’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-250,000
Closed -$2.82M – 45
2025
Q2 		$2.82M Sell
250,000
-462,254
-65% -$5.01M 0.67% 21
2025
Q1 		$7.19M Buy
+712,254
New +$7.7M 2.14% 16
2024
Q4 		– Sell
-2,442,962
Closed -$28.2M – 73
2024
Q3 		$28.2M Sell
2,442,962
-507,038
-17% -$5.77M 1.66% 14
2024
Q2 		$31.2M Buy
+2,950,000
New +$32.3M 3.06% 9

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PSC
Patient Square Capital Menlo Park, California $564M AUM 261.3% 1-Year Est. Return

Troluce Capital Advisors's ROIV Position: Q3 2025 in Review

Troluce Capital Advisors sold out of Roivant Sciences (ROIV) in Q3 2025, closing a stake of 250,000 shares — an estimated $2.82M sold.

Troluce Capital Advisors first reported a position in ROIV in Q2 2024 and held it in 4 quarters. The position peaked at $31.2M in Q2 2024. 337 funds tracked by Wall St. Rank hold ROIV as of Q3 2025.

  • Troluce Capital Advisors reported no remaining Roivant Sciences position as of Q3 2025 after selling out during the quarter.
  • Troluce Capital Advisors sold 250,000 Roivant Sciences shares in Q3 2025, an estimated $2.82M.
  • Troluce Capital Advisors first reported a position in Roivant Sciences in Q2 2024 and held it in 4 quarters.
  • Troluce Capital Advisors's Roivant Sciences position peaked at $31.2M in Q2 2024.
  • 337 funds tracked by Wall St. Rank held Roivant Sciences as of Q3 2025.

Based on Troluce Capital Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.